Oncotarget

Research Papers:

Identification of novel tumor suppressor proteases by degradome profiling of colorectal carcinomas

Julia M. Fraile, Gonzalo R. Ordoñez, Pedro M. Quiros, Aurora Astudillo, Jose A. Galvan, Dolors Colomer, Carlos Lopez-Otin, Jose M.P. Freije and Xose S. Puente _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2013; 4:1919-1932. https://doi.org/10.18632/oncotarget.1303

Metrics: PDF 2086 views  |   HTML 2403 views  |   ?  


Abstract

Julia M. Fraile1, Gonzalo R. Ordóñez1, Pedro M. Quirós1, Aurora Astudillo2, José A. Galván3, Dolors Colomer4, Carlos López-Otín1, José M.P. Freije1 and Xose S. Puente1

1 Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología, Universidad de Oviedo, 33006-Oviedo, Spain,

2 Servicio de Anatomía Patológica, Instituto Universitario de Oncología, Hospital Universitario Central de Asturias, Oviedo, Spain,

3 Banco de Tumores, Instituto Universitario de Oncología, Hospital Universitario Central de Asturias, Oviedo, Spain,

4 Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.

Correspondence:

Xose S. Puente, email:

Jose M.P. Freije, email:

Keywords: proteolysis, metastasis, invasion, cancer

Received: August 20, 2013 Accepted: September 13, 2013 Published: September 15, 2013

Abstract

Proteolytic enzymes play important roles during tumor development and progression through their ability to promote cell growth or by facilitating the invasion of surrounding tissues. The human genome contains more than 570 protease-coding genes, many of them forming functional networks, which has forced the use of global strategies for the analysis of this group of enzymes. In this study, we have designed a new quantitative PCR-based device for profiling the entire degradome in human malignancies. We have used this method to evaluate protease expression levels in colorectal carcinomas with the finding that most proteases with altered expression in these tumors exert their function in the extracellular compartment. In addition, we have found that among genes encoding repressed proteases there was a higher proportion with somatic mutations in colorectal cancer when compared to genes coding for upregulated proteases (14% vs. 4%, p<0.05). One of these genes, MASP3, is consistently repressed in colorectal carcinomas as well as in colorectal cancer cell lines when compared to normal colonic mucosa. Functional analysis of this gene revealed that ectopic expression of MASP3 reduces cell proliferation in vitro and restrains subcutaneous tumor growth, whereas its downregulation induces an increase in the tumorigenic potential of colorectal cancer cells. These results provide new insights into the diversity of proteases associated with cancer and support the utility of degradome profiling to identify novel proteases with tumor-defying functions.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 1303